Clinical Trials/NCT03402178

NCT03402178

Terminated

Phase 1

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

Eisai Co., Ltd.1 site in 1 country118 target enrollmentDecember 21, 2017

ConditionsHealthy Participants

InterventionsE2082 Placebo

DrugsE2082 Placebo

Overview

Phase: Phase 1
Intervention: E2082
Conditions: Healthy Participants
Sponsor: Eisai Co., Ltd.
Enrollment: 118
Locations: 1
Primary Endpoint: Part A: Mean value of the maximum observed concentration (Cmax) of E2082 under a fasted state for the single ascending dose (SAD) Cohorts 1-10
Status: Terminated
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study will be conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending oral doses of E2082 in healthy Japanese adult and elderly male participants, and to evaluate the safety, tolerability, and PK of multiple ascending oral doses of E2082 in healthy Japanese and Caucasian adult male participants.

Registry

clinicaltrials.gov

Start Date

December 21, 2017

End Date

February 20, 2020

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Male

Investigators

Sponsor

Eisai Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants must meet all of the following criteria to be included in this study:
•Non-smoking, age ≥20 years and \<55 years old adult male (Cohorts 1 to 9 of Part A and all cohorts of Part B), or age ≥55 years and ≤85 years old elderly male (only Cohort 10 of Part A) at the time of informed consent. To be considered non-smokers, participants must have discontinued smoking for at least 4 weeks before dosing.
•Body mass index ≥18 and \<30 kilograms per meters squared at Screening

Exclusion Criteria

•Participants who meet any of the following criteria will be excluded from this study:
•Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
•Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of E2082, example, hepatectomy, nephrectomy, and digestive organ resection
•Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, electrocardiogram finding, or laboratory test results that require medical treatment at Screening

Arms & Interventions

E2082

E2082 will be administered as a solution (0.2 milligram \[mg\]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.

Intervention: E2082

E2082-matched placebo

Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.

Intervention: Placebo

Outcomes

Primary Outcomes

Part A: Mean value of the maximum observed concentration (Cmax) of E2082 under a fasted state for the single ascending dose (SAD) Cohorts 1-10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.

Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.

Part A: Mean value of AUC(0-t) under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose

AUC(0-t) represents the total drug exposure from zero time to the time of the last quantifiable concentration.

Part A: Mean value of AUC(0-96h) under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours postdose

AUC(0-96h) represents the total drug exposure from zero time to 96 hours after dosing.

Part A: Mean value of Cmax of E2082 under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose

Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.

Part A: Mean value of AUC from zero time to 72 hours after dosing (AUC[0-72h]) under a fasted state for the SAD Cohorts 1-10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours postdose

AUC(0-72h) represents the total drug exposure from zero time to 72 hours after dosing.

Part A: Mean value of AUC(0-inf) under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose

AUC(0-inf) represents the total drug exposure from zero time extrapolated to infinite time.

Part B: Mean value of Tmax of E2082 for the MAD cohorts on Day 1

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1

Tmax is the time at which the highest concentration of E2082 occurs.

Part A: Mean value of the time at which the highest plasma concentration (Tmax) of E2082 occurs under a fasted state for the SAD Cohorts 1-10

Tmax is the time at which the highest concentration of E2082 occurs.

Part A: Mean value of Tmax of E2082 under fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose

Tmax is the time at which the highest concentration of E2082 occurs.

Part A: Mean value of the area under the concentration-time curve from zero time to 24 hours after dosing (AUC[0-24h]) under a fasted state for the SAD Cohorts 1-10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose

AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.

Part A: Mean value of terminal elimination phase half-life (t½) of E2082 under a fasted state for the SAD Cohorts 1-10

t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.

Part B: Change from baseline in QT interval corrected for heart rate using the Fridericia formula (QTcF)

Time Frame: Baseline and Day 10

Part A: Mean value of AUC from zero time to the time of the last quantifiable concentration (AUC[0-t]) under a fasted state for the SAD Cohorts 1-10

AUC(0-t) represents the total drug exposure from zero time to the time of the last quantifiable concentration.

Part A: Mean value of AUC(0-24h) under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose

AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.

Part A: Mean value of AUC(0-72h) under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours postdose

AUC(0-72h) represents the total drug exposure from zero time to 72 hours after dosing.

Part A: Mean value of AUC from zero time to 96 hours after dosing (AUC[0-96h]) under a fasted state for the SAD Cohorts 1-10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours postdose

AUC(0-96h) represents the total drug exposure from zero time to 96 hours after dosing.

Part B: Mean value of AUC(0-24h) after dosing on Day 1 for the MAD cohorts

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1

AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.

Part B: Mean value of AUC(0-τ) for the MAD cohorts

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours postdose of Day 10

AUC(0-τ) is AUC over the dosing interval on multiple dosing.

Part B: Mean value of t½ following the last day of dosing for the MAD cohorts

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.

Part B: Accumulation ratio for AUC and Cmax (Rac) for the MAD cohorts

Time Frame: Predose at Days 1, 2, 6, 10, 12, 13, and 14. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

Rac (Cmax) is calculated as the ratio of drug concentrations observed during a dosing interval at steady-state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (AUC)=steady state AUC(0-τ)/single dose AUC(0- τ), where τ is dosing interval.

Part B: Mean value of apparent total clearance at steady state (CLss/F) for the MAD cohorts on Day 10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

CLss/F is the apparent total clearance at steady state following extravascular (example, oral) administration. It is defined as the rate of drug elimination.

Part B: Mean value of Vz/F for the MAD cohorts on Day 10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

Vz/F is apparent volume of distribution at terminal phase on Day 10.

Part A: Mean value of AUC from zero time extrapolated to infinite time (AUC[0-inf]) under a fasted state for the SAD Cohorts 1-10

AUC(0-inf) represents the total drug exposure from zero time extrapolated to infinite time.

Part A: Mean value of t½ of E2082 under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose

t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.

Part A: Mean value of apparent total clearance (CL/F) of E2082 under a fasted state for the SAD Cohorts 1-10

CL/F is the apparent total clearance following extravascular (example, oral) administration.

Part A: Mean value of CL/F of E2082 under a fasted state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose

CL/F is the apparent total clearance following extravascular (example, oral) administration.

Part A: Mean value of the apparent volume of distribution at terminal phase of E2082 on Day 1 (Vz/F) under a fasted state for the SAD Cohorts 1-10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose

The apparent volume of distribution gives information about the amount of drug distributed in body tissue rather than the plasma.

Part A: Mean value of Vz/F of E2082 on Day 1 under a fed state for the SAD Cohort 5

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose

The apparent volume of distribution gives information about the amount of drug distributed in body tissue rather than the plasma.

Part B: Mean value of Cmax of E2082 for the multiple ascending dose (MAD) cohorts on Day 1

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1

Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.

Part B: Mean value of Cmax of E2082 at steady state (Css,max) for the MAD cohorts on Day 10

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.

Part B: Mean value of the minimum observed concentration (Cmin) of E2082 for the MAD cohorts on Day 1

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1

Cmin is the minimum observed concentration of E2082 in the plasma that is measured after a dose.

Part B: Mean value of the average steady state concentration (Css,av) of E2082 for the MAD cohorts

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 10

The average steady state concentration is calculated as AUC(0-τ)/τ. τ is the dosing interval.

Part B: Mean value of Cmin of E2082 at steady state (Css,min) for the MAD cohorts

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

Css,min is the minimum observed concentration of E2082 in the plasma that is measured after a dose at steady state.

Part B: Mean value of Tmax of E2082 at steady state (Tss,max) for the MAD cohorts

Time Frame: Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10

Tss,max is the time at which the highest concentration of E2082 occurs at steady state.

Part B: Peak-trough fluctuation (PTF) for the MAD cohorts

PTF is peak to trough fluctuation at steady-state.

Secondary Outcomes

Change-from-baseline in heart rate (HR)(Baseline, Days 1 and 10)
Change from baseline in PR interval and QRS interval of the Electrocardiogram (ECG)(Baseline, Days 1 and 10)
Placebo-corrected change from baseline in HR(Baseline, Days 1 and 10)
Placebo-corrected change from baseline in QTcF, PR, QRS interval(Baseline, Days 1 and 10)
Number of participants with categorical outliers for HR, PR interval, QRS interval(Baseline up to Day 11)
Number of participants with categorical outliers defined as QTcF >450 msec, 480 msec and 500 msec at any timepoint and change-from-baseline QTcF (ΔQTcF) >30 msec (increased by 30 msec) and >60 msec(Baseline up to Day 11)
Number of participants with T wave morphology changes(Baseline up to Day 11)
Number of participants with U-wave presence(Baseline up to Day 11)